Home > Result Summaries: Compounds > ropinirole > Result Summary for ROR104836

Result Summary for ROR104836

Result Summary

Protocol ID:	ROR104836
Clinical Study ID:	ROR104836
Official Title:	A parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome.
Phase:	phase 4
Study Indications or Diseases:	Restless Legs Syndrome
Generic Name:	ropinirole
Trade/Product Name:	Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Diego García-Borreguero, Birgit Högl, Luigi Ferini-Strambi, John Winkelman, Christina Hill-Zabala, Afsaneh Asgharian, Richard Allen. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. [Mov Disord]. 2012;27(2):277-283.